These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 9989585

  • 1. Interaction between class B beta-lactamases and suicide substrates of active-site serine beta-lactamases.
    Prosperi-Meys C, Llabres G, de Seny D, Soto RP, Valladares MH, Laraki N, Frere JM, Galleni M.
    FEBS Lett; 1999 Jan 25; 443(2):109-11. PubMed ID: 9989585
    [Abstract] [Full Text] [Related]

  • 2. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
    Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA.
    Antimicrob Agents Chemother; 2010 Feb 25; 54(2):890-7. PubMed ID: 20008772
    [Abstract] [Full Text] [Related]

  • 3. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S, Nicolas-Chanoine MH, Labia R.
    FEMS Microbiol Lett; 1996 Sep 15; 143(1):29-33. PubMed ID: 8807798
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC.
    FEBS Lett; 2000 Mar 31; 470(3):285-92. PubMed ID: 10745083
    [Abstract] [Full Text] [Related]

  • 5. Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.
    Li R, Wang YT, Chen CL.
    J Mol Model; 2013 Jun 31; 19(6):2519-24. PubMed ID: 23455927
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interactions between active-site-serine beta-lactamases and mechanism-based inactivators: a kinetic study and an overview.
    Matagne A, Ghuysen MF, Frère JM.
    Biochem J; 1993 Nov 01; 295 ( Pt 3)(Pt 3):705-11. PubMed ID: 8240281
    [Abstract] [Full Text] [Related]

  • 8. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.
    Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y.
    Antimicrob Agents Chemother; 1993 Apr 01; 37(4):851-8. PubMed ID: 8388201
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
    Sun T, Bethel CR, Bonomo RA, Knox JR.
    Biochemistry; 2004 Nov 09; 43(44):14111-7. PubMed ID: 15518561
    [Abstract] [Full Text] [Related]

  • 11. Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
    Denny BJ, Toomer CA, Lambert PA.
    Microbios; 1994 Nov 09; 78(317):245-57. PubMed ID: 8078414
    [Abstract] [Full Text] [Related]

  • 12. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M, Lindqvist L, Tunér K, Nord CE.
    J Antimicrob Chemother; 1992 Jul 09; 30(1):17-25. PubMed ID: 1331018
    [Abstract] [Full Text] [Related]

  • 13. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS, Taracila MA, Totir MA, Bonomo RA, Buynak JD, van den Akker F, Carey PR.
    Biochemistry; 2007 Jul 24; 46(29):8689-99. PubMed ID: 17595114
    [Abstract] [Full Text] [Related]

  • 14. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS, Totir MA, Carey MP, Hujer AM, Bonomo RA, Carey PR.
    Biochemistry; 2003 Nov 25; 42(46):13386-92. PubMed ID: 14621983
    [Abstract] [Full Text] [Related]

  • 15. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA, Cha J, Ishiwata A, Wang B, Sheri A, Anderson VE, Buynak J, Mobashery S, Carey PR.
    Biochemistry; 2008 Apr 01; 47(13):4094-101. PubMed ID: 18324783
    [Abstract] [Full Text] [Related]

  • 16. 6-(hydroxyalkyl)penicillanates as probes for mechanisms of beta-lactamases.
    Golemi D, Maveyraud L, Ishiwata A, Tranier S, Miyashita K, Nagase T, Massova I, Mourey L, Samama JP, Mobashery S.
    J Antibiot (Tokyo); 2000 Oct 01; 53(10):1022-7. PubMed ID: 11132946
    [Abstract] [Full Text] [Related]

  • 17. A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
    Perilli M, Franceschini N, Bonfiglio G, Segatore B, Stefani S, Nicoletti G, Perez MM, Bianchi C, Zollo A, Amicosante G.
    J Enzyme Inhib; 2000 Oct 01; 15(1):1-10. PubMed ID: 10850951
    [Abstract] [Full Text] [Related]

  • 18. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G, Mascaretti O, Radice M, Power P, Calcagno ML, Mata EG, Gutkind G.
    J Antimicrob Chemother; 1998 Feb 01; 41(2):313-5. PubMed ID: 9533481
    [No Abstract] [Full Text] [Related]

  • 19. A comparative study of class-D beta-lactamases.
    Ledent P, Raquet X, Joris B, Van Beeumen J, Frère JM.
    Biochem J; 1993 Jun 01; 292 ( Pt 2)(Pt 2):555-62. PubMed ID: 8389139
    [Abstract] [Full Text] [Related]

  • 20. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Fonseca F, Sarmento AC, Henriques I, Samyn B, van Beeumen J, Domingues P, Domingues MR, Saavedra MJ, Correia A.
    Antimicrob Agents Chemother; 2007 Dec 01; 51(12):4512-4. PubMed ID: 17875998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.